TW397683B - Treatment of inflammatory bowel disease using oral dosage forms of <omega>-3 polyunsaturates acids - Google Patents
Treatment of inflammatory bowel disease using oral dosage forms of <omega>-3 polyunsaturates acids Download PDFInfo
- Publication number
- TW397683B TW397683B TW085105489A TW85105489A TW397683B TW 397683 B TW397683 B TW 397683B TW 085105489 A TW085105489 A TW 085105489A TW 85105489 A TW85105489 A TW 85105489A TW 397683 B TW397683 B TW 397683B
- Authority
- TW
- Taiwan
- Prior art keywords
- oral dosage
- dosage form
- acid
- dha
- item
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
五、 發明説明( A7 B7 (1997年丨0月修正) 經濟部中央榇準局月工消費合作社印裝 例示爲纖維素乙酸酯酞酸酯/酞酸乙酯,但參考於以聚丙 烯酸甲酯爲包覆材料之用途。 Belluzzi 等(Dig. Dis. Sci 3_i_ ( 1 9 9 4 ) 2 5 8 9 -2594)報告5組Crohn氏病患者治療用: A組:含500mg Purepa濃魚油(含40%EPA及 20 % DHA)之無包衣膠囊, B組:含500mg Purepa濃魚油膠囊包覆以 PH5. 5/120分或纖維素乙酸酯三苯甲酸酯(CAT)。 C組:含50Qmg Purepa濃魚油膝囊包覆以 PH5.5/60 分 CAT D組:含500mg Purepa濃魚油膠囊包覆以 pH6.9/120分纖維乙酸酯酞酸酯(CAP); E組:含lOOOmg Max-EPA三甘油酯魚油(EPA 1 8 %及D H A 1 0 % )之無包衣膠囊。 CAP在pH6.8,CAT在pH5.5溶解》所有包衣膠囊 在相關pH15分內崩解。 四組6週內每日3次每餐服用膠囊A-D 9個(2.7克亞 美加-3多元未飽和酸),另一組膠囊E 12個(3.4克亞美 加-3多元未飽和酸)。 五組均藉取代二十碳四烯酸,亞麻仁油酸及少部分油 酸來增加血漿及紅血球磷脂質膜中亞美加-3多元未飽和 酸的結合。但用含Purepa濃魚油之膠囊時比用Max-EPA三 甘油酯混合物更多自由亞美加·3多元未飽和脂肪酸混合 物被吸收。此加入與包覆相關,尤其與膠囊崩解地點相 -5- MUt尺/1適用中國國家標準(CNS ) Α4^4«· ( 210X297公釐} « IV —ϋ (請先W讀背面之注^h項再填寫本頁) 、1Τ - 經濟部中央樣準局員工消费合作社印製 A7 B7 五、發明説明(4 ) 1 本發明爲有關亞美加-3多元未飽和酸,尤其 5,8,11,14,17-二十-碳五烯酸(£?人)及/或 4,7, 10, 13, 16, 19 -二十二碳六烯酸(DHA)之口服。尤 其提供亞美加-3多元未飽和酸之經腸劑型,用以治療腸 炎疾病,尤其Crohn氏病及潰瘍性大腸炎。 已知DHA,EPA及其他亞美加-3多元未飽和酸用以 治療腸炎疾病(見如EP-A-0244832,EP-A- 0289204, EP-A-0311091 及 WO-A-93/21912)。 E P - A - 0 2 4 4 8 3 2記載含某不飽和脂肪酸及某特殊刺 激劑之醫藥組成物,用以治療隨伴前列腺素缺乏之疾病, 尤其胃腸潰瘍。此不飽和脂肪酸有3-5個分離雙鏈,在直 鏈有 18-22個碳,在2, 3, 4, 16, 17, 18, 19或20位之一 或二個碳能甲基化或乙基化,例如EPA。參照含聚苯乙 烯或聚丙烯系衍生物之pH依賴徐放性處方及腸溶衣製 品。 EP-A-0289204記載含C18.22多元未飽和脂肪酸之 鋰鹽之醫藥組成物,特定之多元未飽和脂肪酸包括DHA 及E P A。此組成物可經腸,非經腸及局部授予,用以治 療對鋰及/或多元未飽和脂肪酸治療有效之病,例如 Crohn氏病及潰瘍性大腸炎。參照例如丙烯酸酯或纖維 素乙酸酯酞酸酯之腸溶液使該鹽徐放至小腸。 E P - A - 0 3 1 1 0 9 1記載生理容許等張性脂肪乳液,內 含美加-3 -脂肪酸或酯,中長鏈三甘油酯及乳化劑。此脂 -3- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公嫠) ——-•^^^1 ^ϋ· nn ^^^1 ti4 1^1 ^^^1 nn ^l_i--eJ (請先閲讀背面之注意事項再填寫本頁) 經 五、發明説明( (〇
A7 B7 (1997年丨0月修正) 表2 患者臨床特徵· P U RE P A 安慰藥 男 2 0 19 女 19 2 0 年齡 3 4 ( 1 8 - 6 7 ) 39(20-65) 吸煙者 14/39 13/39 病期(月;中値(範圍)) 6 8 ( 2 4 - 9 4 ) 66(20-88) 先前開刀< 1 m 14/39 13/39 部位 回腸 2 5 2 4 回腸+結腸 14 15 C D AI中値(範圍) 78(28-120) 82(30-112) E S R 3 6.9 3 5.7 (m m / h ) (SD24-最低6 ;最高122) (SD24-最低12 ;最高90) α - 2 9.6 9 . 2 球蛋白(g/ι) (SD1.8-最低 6.1;最高 13·2) (SD1.3-最低 6.5;最高 11.9) α - 1 13 6.8 13 7.1 糖蛋白(mg/dl) (SD52-最低53 ;最高257) (SD58-最低60 ;最高263) 請 先 閱 讀 背 面 之 注 2 旁 訂 央 樣 率 扁 Ά X 消 费 合 作 社 印 掣 魚油組各患者每日接受1.8克EP A及0.9克DHA,一連1 2 個月,而在硏究開始,3,6及12個月時檢査,若症狀惡化 CADI比基線値增加至少1〇〇分,且大於150分2週以上時提 早檢查。每次來院測試血液,腎,肝,ESR,α-1酸糖蛋 -11 木认佐尺度適用中囡國家標準(CNS ) Α4规格(210X297公釐) A7 B7 五、發明説明() 2 肪酸或酯成分可呈純化合物或魚油形態,宜爲EPA。此 乳液非經腸授予來治療慢性腸炎疾病。 WO-A-93/21912記載非經腸授予含多元未飽和長 鏈亞美加-3-脂肪酸或酯之乳液來治療包括腸炎疾病等炎 症之用途。此脂肪酸或酯可以魚油存在,宜爲包括DHA 及EP A之脂肪酸。 含D Η A或E P A之腸溶性製品用於治療其他病況(見 EP-A-0336612 , GB-A-2090529 > JP-A-62201823 及 WO-A-90/04391)。 EP-A-0336662記載腸溶液內魚油酸之微包囊,提 供安定,無臭,無味組成物加入食品以降低血中三甘油 酯,低密度脂蛋白質及膽固醇濃度。此特定包覆材料爲乙 基纖維素,纖維素乙酸酯酞酸酯及纖維素乙酸酯苯三甲酸 酯。參照幽門下之小腸上部之活性釋放,但針對回腸之釋 放則無特別參考。 GB-A-2090529記載用DHA或其酯或醯胺防治栓 塞,參考其中腸溶衣錠及膜衣錠之一般名詞。 經濟部中央標準局員工消费合作社印製 (請先聞讀背面之注意事項再填寫本頁) JP-A-622〇l823記載腸溶膠囊來治療腸內異常發酵 或下痢,其在油內含細菌。此油可爲EPA,而一些腸溶 材料爲特定者,包括蟲膠,羧甲基纖維素,纖維素乙酸酯 酞酸酯,羥甲基丙基纖維素酞酸酯及聚乙烯醇酞酸酯。 WO-A-90/04391(及對應之 GB-A-2223943)記 載EPA,DHA及其他亞美加-3多元未飽和脂肪酸之腸溶 劑型來克服口服這些酸隨伴之打嗝及氣脹等問題。包覆之 -4- 本紙張尺度通用中國國家橾準(CNS > A4規格(21〇X:297公釐) 五、 發明説明( A7 B7 (1997年丨0月修正) 經濟部中央榇準局月工消費合作社印裝 例示爲纖維素乙酸酯酞酸酯/酞酸乙酯,但參考於以聚丙 烯酸甲酯爲包覆材料之用途。 Belluzzi 等(Dig. Dis. Sci 3_i_ ( 1 9 9 4 ) 2 5 8 9 -2594)報告5組Crohn氏病患者治療用: A組:含500mg Purepa濃魚油(含40%EPA及 20 % DHA)之無包衣膠囊, B組:含500mg Purepa濃魚油膠囊包覆以 PH5. 5/120分或纖維素乙酸酯三苯甲酸酯(CAT)。 C組:含50Qmg Purepa濃魚油膝囊包覆以 PH5.5/60 分 CAT D組:含500mg Purepa濃魚油膠囊包覆以 pH6.9/120分纖維乙酸酯酞酸酯(CAP); E組:含lOOOmg Max-EPA三甘油酯魚油(EPA 1 8 %及D H A 1 0 % )之無包衣膠囊。 CAP在pH6.8,CAT在pH5.5溶解》所有包衣膠囊 在相關pH15分內崩解。 四組6週內每日3次每餐服用膠囊A-D 9個(2.7克亞 美加-3多元未飽和酸),另一組膠囊E 12個(3.4克亞美 加-3多元未飽和酸)。 五組均藉取代二十碳四烯酸,亞麻仁油酸及少部分油 酸來增加血漿及紅血球磷脂質膜中亞美加-3多元未飽和 酸的結合。但用含Purepa濃魚油之膠囊時比用Max-EPA三 甘油酯混合物更多自由亞美加·3多元未飽和脂肪酸混合 物被吸收。此加入與包覆相關,尤其與膠囊崩解地點相 -5- MUt尺/1適用中國國家標準(CNS ) Α4^4«· ( 210X297公釐} « IV —ϋ (請先W讀背面之注^h項再填寫本頁) 、1Τ - 經濟部中央標準局員工消费合作社印製 A7 B7 五、發明説明(,) 4 關。C組膠囊(pH5. 5/60包覆)得血漿及紅血球磷脂質膜 中加入亞美加-3多元未飽和脂肪酸最佳。D組膠囊(pH 6. 9包覆)加入極差,有70%病人增加每日腸動。B組膠 囊(pH5. 5/120分包覆)之加入稍佳,但有5位病人有 5 0 %下痢。 C組膠囊由Belluzzi等倂用pH及時間依附釋放機制 使其能在胃十二指腸避免膠囊破裂(PH5. 5),結果免於 上部胃腸副作用。因其只耐胃60分,故在小腸迅速放出 濃魚油而完全吸收。 .現在驚奇地發現若在回腸控制多元未飽和脂肪酸之放 出,則得吸收及無副作用之最佳配合。 故本發明提供口服劑型,內含活性成分亞美加-3多元 未飽和酸呈自由酸型或其製藥容許鹽,此在回腸放出該 酸。 本發明也提供用亞美加-3多元未飽和酸呈自由酸型或 其製藥容許鹽,以製造在回腸放出該酸之治療腸炎之醫 藥。 本發明又提供該口服劑型治療腸炎之用途。 亞美加-3多元未飽和酸宜爲DHA,EPA或其混合 物。此以自由酸或其製藥容許鹽存在,可爲惟一活性成分 或配合其他活性成分。宜用含至少60重量% DHA及EPA 之濃魚油。 -6- 本紙張尺度適用中國囷家標準(CNS ) A4规格(210X297公釐) n· Maemmmmw ^^^1 m·· —ai-·· ml ^^^1 I— (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局負工消費合作社印製 A7 _B7__ 五、發明説明(c ) 5 亞美加-3多元未飽和酸易氧化,故常加抗氧化劑,宜 r-生育酚,但也可用其他藥理容許抗氧化劑,如丁基化 羥甲氧苯,丁基化羥甲苯,五倍子酸丙酯或嘢。 口服製劑依劑型之性質也可含一種以上製藥容許賦形 劑。口服製劑宜爲含微包囊型或載於適當吸收劑之亞美加 -3多元未飽和酸之包衣錠。但宜包衣膠囊,尤其軟膠 囊,更宜硬膠囊。 此包衣須在回腸,宜中回腸放出該酸。包衣之溶解一 般完全依時間,但也可用倂依時間及pH之包衣。包衣宜 在pH5. 5耐30〜60分。本適宜包衣之中性聚丙烯酸酯,' 如聚(丙烯酸乙酯-甲基丙烯酸甲酯),尤其平均分子量約 800,000^.Eudragit NE 3 0 - D (Rohm Pharma GmbH)。 一般,亞美加-3不飽和酸每日劑量爲20-50 mg/kg,尤其30~40kg 〇實際劑量乃視亞美加_3多元未 飽和酸之種類及病之性質及程度而異。一般各單位劑量含 250~1000mg,尤其 400~800mg。 例1 於透明硬膠囊(Elanco Qualicaps 0號,法國禮來 SA)各裝塡500mg濃魚油含至少60重量%DHA及 EPA(Incromega 3 F 6 0 , Croda Universal 公司,英 國)。此膠囊以Eudragit®NE 30-D與包膜組成物(下 本紙張尺度適用中國國家榇準(CNS ) A4規格(210X297公釐) nn ^^^1 1^1 ^^^1 ^^^1 I ^^^1 m· (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局負工消費合作社印製 A7 B7 五、發明説明() 〇 述)在25 τ 0.8巴壓力,35ml /分噴霧後在25 °C風乾至 少_3 0分,得在ρΗ5·5耐30〜60分之包膜。 此包膜組成物(供50, 000個膠囊)之製備乃將矽消泡 乳液(〇.36mg)’褐色氧化鐵(Ε 172,3.00mg)’二氧 化鈦2.35mg及滑石l〇mg連續徐徐加入水75mg,並攪 拌1〜2小時來生成極細分散液。將平均分子量約 8 0 0,0 0 0 (Eudragit®NE 30D 60mg)之聚(丙烯酸乙 酯-甲基丙烯酸甲酯)之3 0 %水懸浮液加入少許水中之聚 花楸酸酯80 (M055F,0.2mg)而攪拌後,加矽消泡乳 液(2或3滴)來消泡,而徐徐加上述水懸浮液。容器以水 25mg洗淨,過濾(150/zm)前,攪拌30分。 例2 用臨床上通用以診斷Crohn氏病之依Crohn氏病活 性指數(C D A T )而滿足下列基準對7 8名患者進行雙盲安 慰藥控制無規硏究: (a) CDAIC150 至少3個月,但少於2年; (b) 至少一不正常値酸糖蛋白(> 130mg/dl),血淸(ESR); (c ) (>40mm/h),或 α-2 球蛋白(> 0 . 9 g / d 1); (d)在前3個月無處理以5 -胺基柳酸酯, suiphasalazine或皮質類固醇,或在6個 月前予以免疫抑制治療; -8- 本紙張尺度適用中國國家標準(CNS ) Α4规格(210X297公釐) (請先閲讀背面之注意事項再填寫本頁)
、1T A7B7 五、發明説明( (e) 無先前開腹>lm; (f) 年齡18-75歲。 39名患者無規分爲2組,每日接受含5〇〇mg濃魚油( “Purepa”,見表1)之腸溶性硬膠囊9個,或含5〇〇mg安 慰(Miglyol®812)同外觀之腸溶膠囊9個。濃魚油含 40%EPA 及 20DHA。二組膠囊皆包覆Eudragit NE 30D使耐胃酸或汁至少30分,在pH5. 5 60分內崩散, 而在小腸放出魚油。治療中患者不服任何其他藥物。二組 之臨床特徵如表2。 n n n· n I 11 V (请先閲讀背面之注意事項再填寫本頁) -1 、 -# 經濟部中央樣準局員工消费合作社印製 -9- 本紙張尺度適用中國國家梯準(CNS ) A4規格(210X297公釐) 五、發明説明( A7 B7 經濟部中央標準局員工消費合作社印製 脂 1質 自由 酸 C 1 4 :0 - C 1 6 :0 0 .4 C 1 6 :1 3 .2 C 1 6 :2 2 .1 C 1 6 :3 2 .4 C 1 6 :4 5 .2 C 1 8 :0 - C 1 8 :1 0 .8 C 1 8 :2 1 .5 C 1 8 : :3 1 .3 C 1 8 : 4 6 .9 C 2 0 : 1 C 2 0 : 3 1 . 5 C 2 0 : 4( A A) 1 . 7 C 2 0 : 5 ( E PA) 4 2 .4 C 2 1 : 5 1 . 6 C 2 2 : 5 0 . 5 C 2 2 : 6( D H A ) 19 .9 表1 膠囊內容之組成
Purepa(魚油)Migly〇l(安慰藥) » 中性油 10- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) — .-I- m —ϋ - - n m m· n m m SI ^ 、\$ (請先閲讀背面之注意事項再填寫本頁) 經 五、發明説明( (〇
A7 B7 (1997年丨0月修正) 表2 患者臨床特徵· P U RE P A 安慰藥 男 2 0 19 女 19 2 0 年齡 3 4 ( 1 8 - 6 7 ) 39(20-65) 吸煙者 14/39 13/39 病期(月;中値(範圍)) 6 8 ( 2 4 - 9 4 ) 66(20-88) 先前開刀< 1 m 14/39 13/39 部位 回腸 2 5 2 4 回腸+結腸 14 15 C D AI中値(範圍) 78(28-120) 82(30-112) E S R 3 6.9 3 5.7 (m m / h ) (SD24-最低6 ;最高122) (SD24-最低12 ;最高90) α - 2 9.6 9 . 2 球蛋白(g/ι) (SD1.8-最低 6.1;最高 13·2) (SD1.3-最低 6.5;最高 11.9) α - 1 13 6.8 13 7.1 糖蛋白(mg/dl) (SD52-最低53 ;最高257) (SD58-最低60 ;最高263) 請 先 閱 讀 背 面 之 注 2 旁 訂 央 樣 率 扁 Ά X 消 费 合 作 社 印 掣 魚油組各患者每日接受1.8克EP A及0.9克DHA,一連1 2 個月,而在硏究開始,3,6及12個月時檢査,若症狀惡化 CADI比基線値增加至少1〇〇分,且大於150分2週以上時提 早檢查。每次來院測試血液,腎,肝,ESR,α-1酸糖蛋 -11 木认佐尺度適用中囡國家標準(CNS ) Α4规格(210X297公釐) 經濟部中央標準局員工消费合作社印製 A7 B7 五、發明説明(1C)) 白,α-2球蛋白及CRP(c-AMP-受體-蛋白)。在0. 6個 月及終了時,依 Popp-Snijders 等(Scan. J. Clin. Lab. Invest 44_ ( 1 9 8 4 ) 39-46)得 2mi 包裝紅血球及 多核白血球,其膜脂質之萃取乃依Dodge及Phillips (J . Lipids Res. ^_(1967) 667-675)用含 0.01% 丁 基化羥甲苯(2, 6二第三丁基對甲酚)抗氧化劑之2:1氯仿/ 甲醇混液。分離磷脂質及分析亞美加-3多元未飽和脂肪 酸前,樣品在-2 0 °C氮貯存2週以下。用1維薄層層析從該 萃出脂質得磷脂質劃分。樣品點在氧化矽板之一角,以氯 仿/甲醇/乙酸/水(25:14:4:2)展開。分離之磷脂質用 IN K0H /甲醇及三氟化硼/14%甲醇在80_°(:轉甲基化。 次將脂肪酸甲酯以已烷萃取,再懸浮於100μ丨苯,以裝有 毛細柱(0.32mm i.d. X 25m),以氦爲載氣體(流速 3 m 1 /分)用火焰離子化偵測來氣體層析。柱溫以5 °C /分在 1 7 0 - 2 1 0 °C各脂肪酸甲酯與市售標準品比較來鑑定。以 十八酸(1 7 : 0 )爲內標準(1 m g / m 1 )在苯,結果以相對% 表示。 魚油及安慰藥組之復發率之差異對「僅順從」及「欲 治療」用χ2(χ爲希臘字母,讀音爲chi)測試分析。在活 性成分及安慰藥組間患者之差異用Maqn-Whitney U測 試分析,實驗結果以t-測試就成對數據(2尾部測試)分 析。對留在緩解之患者之Kaplan-Maier壽命表曲線依 指定治療計算。曲線中差異由對數分析。對若干變數(試 -12- 本紙張尺度適用中國國家橾準(CNS ) A4規格(210X297公釐) ^m. m··· ϋ^— ^^^1 ^^^1 ^^^1 ^^^1 ^^^1 I 心々 m n (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部中央標準局属工消費合作社印裝 A 7 B7 五、發明説明(11 ) 處理,性別,年齡,先前手術,病之長久)及臨床復發之 間施行多回歸分析,該前程序用以選擇更代表性模式。 在魚油組,1患者除外(移居),4患者因下痢除外。 在安慰藥組1患者因不來院而除外,1患者下痢而除外。 下痢之5例均在開始治療之第1個月出現,減服也症狀無 改善。此下痢可能因膠囊內容物送至腸之遠部,包覆爲依 時間(在p Η 5 . 5時3 0 - 6 0分),故若轉送時間短,則膠囊 更沿腸殘留。 無油組與安慰藥組相較,復發率就顯著減少:χ2 11.75,卩=0.0004(差異41%,95%信賴範圍((:1)16-66)。此差異在欲治療分析也顯著:χ2 9.05, p = 0. 0026(差異 32 % > 9 5 % ( C 1 ) 1 2 - 5 2 )。 臨床結果如表3,腸炎之實驗變數如表4(接受魚油之 患者在開始及12個月而在終了時仍殘留)。在安慰藥組發 生任何疾病活性無顯著減少。表5乃示主要脂肪酸加入磷 脂質膜(AA =二十碳四烯酸及LA =亞麻仁油酸)。多回歸 分析表示僅魚油膠囊顯著影響臨床復發(t = 3. 16, p = 0.002 , F 比値=1〇,p = 〇.〇〇2) ° 魚油膠囊用12個月,與安慰藥相較,Crohn氏病之 臨床復發減少5 〇 %,尤値一提者,患者不到2 4個月,臨 床上緩解實驗發炎。此型患者與正常實驗長期先前緩解相 較,復發危除率大約75 %。 魚油膠囊所示之結果對Crohn氏病防止臨床復發爲最 有效而安全之治療而副作用較少。 -13- 本紙張尺度適用中國國家揉率(CNS )八4規格(加乂297公釐) 83.3.10,000 ----------N ;裝-- (請先閲讀背面之注意事項再填寫本頁)
、1T 397683 A7 B7 五、發明説明(12 ) 表312個月治療後之臨床結果 魚油 安慰藥(n = 39)除外 1 1 緩解 23/38 1 0 / 3 8 中止 4 1 復發包括中止者(欲治療)15/38(39.5 %)* 2 8 / 3 8 ( 7 3.7 %) * χ 2 9.05;ρ = 0.0026 不包括中止者 11/34 = 32.4% 2 7 / 3 7 = 7 3.0 %
X 1 1.75;ρ = 0.0004 — — — — — / 4-裝 I— I I 訂— — I I I 1‘ (請先閲讀背面之注意事項再填寫本頁) 經濟部中央標準局員工消費合作社印製 -14- 83. 3.10,000 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) 3976B〇 a7 _____B7 五、發明説明(13 ) 表4 23名患者授予Purepa 12個月後之緩解 時間0 1 2個月 I I— /L·^ I— n n n n ^ (請先閲讀背面之注f項再填寫本頁) 經濟部中央橾準局貝工消費合作社印製 -15 - E S R ( m m / h ) 37.8(6-122) SD 25 19.5(3-40) SD 11.2 p = 0 . 0 0 0 2 CRP(mg/dl) 3.6(0.2-9.9) SD 3.4 1.0(0.2-3.5) SD 0.9 p = 0 . 0 0 1 ALF A-2 0.91(0.64-1.32) SD 0.15 0.74(0.56-0.91) SD 0.1 球蛋白(g / d 1 ) p = 0 . 0 0 1 A L F A - 1 137(57-248) SD 49 111(69-180) SD 33 糖蛋白(mg/dl) p = 0 · 0 0 2 蛋白素(g/dl) 3.7(3.0-4.4) SD 0.4 4.0 (3.1-4.7) SD 0.35 p = 0 . 0 0 4 W B C 8780(4000-11700) SD 2093 7400(3310-11550) SD 2634 p = 0 . 0 1 83.3.10,000 本紙張尺度適用中國國家揉準(CNS ) A4規格(210X297公釐) 397683 A7 B7 五、發明説明(u) 表5 主脂肪酸加入紅血球之%
PUREPA MIGLYOL 時間0 6個月 時間0 6個月 18:2n-6 LA 10.2+1 7.0+0.8 6.4±0.4 10.6±1.5 9.8±2 11.1±1.5 20:4n-6 AA 13.9±1.5 8.4±1.2 7.1±1.2 13.5±1.3 12.3 土 1.8 14.1±1.2 20:5n-3 EPA 0.2±0.1 4.1±0.3 5.8±0.6 0.3+0.1 0.1+0.1 0.2+0.1 22:6-3DHA 2.9±0.6 7.411.2 11.4 土 1.2 3.2±0.5 2.8±0.7 3.0±0.6 ^—.1 ^^1 In ί ^^1 n I. HI /--- \5^^· (請先閲讀背面之注$項再填寫本頁) 訂 經濟部中央標準局貝工消费合作社印製 -16- 本紙張尺度適用中國國家揉準(CNS ) A4規格(210><297公釐) 83· 3.10,000
Claims (1)
- A8 B8 為^ %修正 397683 C8 D8 (199^51^1) 、申請專利範圍 1.—種用於治療腸炎疾病的口服劑型,包含一具包 衣的膠囊,該膠囊內含一作爲活性成分的自由酸形態之亞 美加-3多元未飽和酸或其製藥容許鹽,其特徵在該膠囊的 包衣爲中性的聚丙烯酸酯且該包衣在PH5 . 5耐3 0 - 6 0分 鐘。 2 .如申請專利範圍第1項之口服劑型,其中該包衣爲 聚(丙烯酸乙酯-甲基丙烯酸甲酯)。 3. 如申請專利範圍第1項之口服劑型,其中該酸爲 DHA,EPA或其混合物。 4. 如申請專利範圍第2項之口服劑型,其中該酸爲 DHA,EPA或其混合物。 5·如申請專利範圍第3項之口服劑型,其中該dhA, EPA或其混合物以至少60% (重量/重量)的用量存在。 經濟部中央箨準局負工消费合作社印製 (請先聞讀背面之注意事項再填寫本頁) 6.如申請專利範圍第4項之口服劑型,其中該dha, EP A或其混合物以至少60% (重量/重量)的用量存在。 _7·如申請專利範圍第1〜6項中任一項之口服劑型,其 中該酸爲以唯一活性成分存在。 •17· 本纸張尺度逍用中國國家梂準(CNS M4规格(210X297公釐} A8 B8 為^ %修正 397683 C8 D8 (199^51^1) 、申請專利範圍 1.—種用於治療腸炎疾病的口服劑型,包含一具包 衣的膠囊,該膠囊內含一作爲活性成分的自由酸形態之亞 美加-3多元未飽和酸或其製藥容許鹽,其特徵在該膠囊的 包衣爲中性的聚丙烯酸酯且該包衣在PH5 . 5耐3 0 - 6 0分 鐘。 2 .如申請專利範圍第1項之口服劑型,其中該包衣爲 聚(丙烯酸乙酯-甲基丙烯酸甲酯)。 3. 如申請專利範圍第1項之口服劑型,其中該酸爲 DHA,EPA或其混合物。 4. 如申請專利範圍第2項之口服劑型,其中該酸爲 DHA,EPA或其混合物。 5·如申請專利範圍第3項之口服劑型,其中該dhA, EPA或其混合物以至少60% (重量/重量)的用量存在。 經濟部中央箨準局負工消费合作社印製 (請先聞讀背面之注意事項再填寫本頁) 6.如申請專利範圍第4項之口服劑型,其中該dha, EP A或其混合物以至少60% (重量/重量)的用量存在。 _7·如申請專利範圍第1〜6項中任一項之口服劑型,其 中該酸爲以唯一活性成分存在。 •17· 本纸張尺度逍用中國國家梂準(CNS M4规格(210X297公釐} 397683經濟部中央揉率局貝工消费合作社印裝 '申請專利範圍 8·—種用於治療腸炎疾病的口服劑型,包含~具包 衣的藤囊’該膠囊內含一作爲活性成分的DHA,EPA或其 混合物或其製薬容許鹽,其中該包衣爲聚(丙烯酸乙酯-甲 基丙烯酸甲酯)物質且該包衣在ρΗ5·5耐30-60分鐘。 9. —種治療腸炎疾病的口服組成物,其係由以上申 請專.利範圍第1〜6項中任一項或第8項之口服劑型所組成。 10. —種治療腸炎疾病的口服組成物,其係由以上 申請專利範圍第7項之口服劑型所組成。 (請先閲讀背面之注意事項再填寫本頁)祕 準 標 家 國 國 中 用 適 釐 公 7 9 2
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9509764.8A GB9509764D0 (en) | 1995-05-15 | 1995-05-15 | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
Publications (1)
Publication Number | Publication Date |
---|---|
TW397683B true TW397683B (en) | 2000-07-11 |
Family
ID=10774461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW085105489A TW397683B (en) | 1995-05-15 | 1996-05-09 | Treatment of inflammatory bowel disease using oral dosage forms of <omega>-3 polyunsaturates acids |
Country Status (23)
Country | Link |
---|---|
US (2) | US5792795A (zh) |
EP (1) | EP0825858B1 (zh) |
JP (1) | JPH11509523A (zh) |
KR (1) | KR100427112B1 (zh) |
CN (1) | CN1104237C (zh) |
AT (1) | ATE294575T1 (zh) |
AU (1) | AU702692B2 (zh) |
BR (1) | BR9608785A (zh) |
CA (1) | CA2221356C (zh) |
CZ (1) | CZ288560B6 (zh) |
DE (1) | DE69634693T2 (zh) |
DK (1) | DK0825858T3 (zh) |
ES (1) | ES2240995T3 (zh) |
GB (1) | GB9509764D0 (zh) |
HU (1) | HU227282B1 (zh) |
IL (1) | IL118240A (zh) |
NO (1) | NO320780B1 (zh) |
PL (1) | PL184085B1 (zh) |
PT (1) | PT825858E (zh) |
SK (1) | SK282062B6 (zh) |
TW (1) | TW397683B (zh) |
WO (1) | WO1996036329A1 (zh) |
ZA (1) | ZA963854B (zh) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6166024A (en) * | 1995-03-30 | 2000-12-26 | Mayo Foundation For Medical Education And Research | Use of topical azathioprine and thioguanine to treat colorectal adenomas |
GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
JP4309045B2 (ja) * | 1997-10-30 | 2009-08-05 | 森下仁丹株式会社 | 不飽和脂肪酸またはその誘導体を内容物とするカプセル製剤およびその製造法 |
ES2201673T3 (es) * | 1998-02-11 | 2004-03-16 | Rtp Pharma Corporation | Combinacion de esteroides y acidos grasos poiinsaturados para el tratamiento de estados inflamatorios. |
US6191154B1 (en) * | 1998-11-27 | 2001-02-20 | Case Western Reserve University | Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases |
GB9901809D0 (en) * | 1999-01-27 | 1999-03-17 | Scarista Limited | Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes |
DE19930030B4 (de) * | 1999-06-30 | 2004-02-19 | Meduna Arzneimittel Gmbh | CO-3-ungesättigte Fettsäuren enthaltende orale Darreichungsform |
US6358939B1 (en) | 1999-12-21 | 2002-03-19 | Northern Lights Pharmaceuticals, Llc | Use of biologically active vitamin D compounds for the prevention and treatment of inflammatory bowel disease |
US6989377B2 (en) | 1999-12-21 | 2006-01-24 | Wisconsin Alumni Research Foundation | Treating vitamin D responsive diseases |
EA200300547A1 (ru) * | 2000-12-06 | 2003-12-25 | С.Л.А.Фарма Аг | Твердые композиции на основе полиненасыщенных жирных кислот |
US6548646B1 (en) * | 2001-08-23 | 2003-04-15 | Bio-Rad Laboratories, Inc. | Reference control for high-sensitivity C-reactive protein testing |
AU2002352726A1 (en) * | 2001-11-15 | 2003-06-10 | Galileo Laboratories, Inc. | Formulations and methods for treatment or amelioration of inflammatory conditions |
US20030118329A1 (en) * | 2001-12-21 | 2003-06-26 | Pere Obrador | Video indexing using high resolution still images |
EP2295529B2 (en) * | 2002-07-11 | 2022-05-18 | Basf As | Use of a volatile environmental pollutants-decreasing working fluid for decreasing the amount of pollutants in a fat for alimentary or cosmetic use |
SE0202188D0 (sv) * | 2002-07-11 | 2002-07-11 | Pronova Biocare As | A process for decreasing environmental pollutants in an oil or a fat, a volatile fat or oil environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
AU2002951913A0 (en) * | 2002-10-08 | 2002-10-24 | Chevis Agriservices & Consulting Pty. Limited | Method of treatment |
US20050152969A1 (en) * | 2004-01-08 | 2005-07-14 | Chiprich Timothy B. | Colored liquid-filled soft capsules and method of manufacture thereof |
DK1706424T3 (da) | 2004-01-12 | 2009-11-02 | Applied Molecular Evolution | FC-region varianter |
WO2005072113A2 (en) * | 2004-01-20 | 2005-08-11 | Harty Richard F | Compositions and methods of treatment for inflammatory diseases |
GB0403247D0 (en) | 2004-02-13 | 2004-03-17 | Tillotts Pharma Ag | A pharmaceutical composition |
GB0413729D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
GB0413730D0 (en) * | 2004-06-18 | 2004-07-21 | Tillotts Pharma Ag | A pharmaceutical composition and its use |
US8758814B2 (en) | 2004-10-08 | 2014-06-24 | Mcneil-Ppc, Inc. | Chewable enteric coated aspirin tablets |
WO2009009040A2 (en) * | 2007-07-06 | 2009-01-15 | Baum Seth J | Fatty acid compositions and methods of use |
US8343753B2 (en) * | 2007-11-01 | 2013-01-01 | Wake Forest University School Of Medicine | Compositions, methods, and kits for polyunsaturated fatty acids from microalgae |
EP2334295B1 (en) | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
WO2010040012A1 (en) * | 2008-10-01 | 2010-04-08 | Martek Biosciences Corporation | Compositions and methods for reducing triglyceride levels |
WO2010042933A2 (en) | 2008-10-10 | 2010-04-15 | Northwestern University | Inhibition and treatment of prostate cancer metastasis |
BRPI1009431A2 (pt) | 2009-03-09 | 2016-03-01 | Pronova Biopharma Norge As | pré-concentrados farmacêuticos e de suplemento alimentar, sistemas de liberação de droga, método de tratamento de pelo menos um problema de saúde em sujeito em necessidade do mesmo e método e sistema |
US9901551B2 (en) * | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
KR101343249B1 (ko) | 2009-04-29 | 2013-12-19 | 아마린 파마, 인크. | 안정한 제약 조성물 및 그의 사용 방법 |
KR101357438B1 (ko) | 2009-04-29 | 2014-02-06 | 아마린 코포레이션 피엘씨 | Epa 및 심혈관 제제를 포함하는 제약 조성물 및 그의 사용 방법 |
ES2661217T3 (es) | 2009-06-15 | 2018-03-28 | Amarin Pharmaceuticals Ireland Limited | Composiciones y métodos para reducir los triglicéridos sin aumentar los niveles de LDL-C en un sujeto en terapia simultánea con estatinas |
BR112012006692B8 (pt) | 2009-09-23 | 2021-05-25 | Amarin Corp Plc | composição farmacêutica compreendendo um derivado de hidróxi de atorvastatina e um óleo compreendendo etil eicosapentaenoato ou etil docosahexaenoato |
JP6116905B2 (ja) * | 2009-10-23 | 2017-04-19 | プロノヴァ・バイオファーマ・ノルゲ・アーエスPronova BioPharma Norge AS | 脂肪酸油混合物の被覆型カプセル剤および錠剤 |
JP2013540156A (ja) | 2010-10-19 | 2013-10-31 | エルセリクス セラピューティクス インコーポレイテッド | 化学感覚受容体リガンドに基づく治療法 |
WO2012074930A2 (en) | 2010-11-29 | 2012-06-07 | Amarin Pharma, Inc. | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
KR101310710B1 (ko) * | 2011-03-23 | 2013-09-27 | 한미약품 주식회사 | 오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물 |
WO2013070735A1 (en) | 2011-11-07 | 2013-05-16 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
US8551551B2 (en) | 2012-01-06 | 2013-10-08 | Perlman Consulting, Llc | Stabilization of omega-3 fatty acids in saturated fat microparticles having low linoleic acid content |
DK2800563T3 (en) | 2012-01-06 | 2018-10-08 | Omthera Pharmaceuticals Inc | DPA Enriched Compositions of Multi-Saturated Omega-3 Fatty Acids in Free Acid Form |
EP2846779A4 (en) | 2012-05-07 | 2015-12-16 | Omthera Pharmaceuticals Inc | STATIN AND OMEGA-3 FATTY ACID COMPOSITIONS |
CN104582698A (zh) | 2012-06-29 | 2015-04-29 | 阿玛林制药爱尔兰有限公司 | 在接受抑制素治疗的受试者中降低心血管事件风险的方法 |
GB201216385D0 (en) | 2012-09-13 | 2012-10-31 | Chrysalis Pharma Ag | A pharmaceutical composition |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
EP2745709A1 (en) * | 2012-12-24 | 2014-06-25 | Abbott Laboratories, Inc. | Nutritional compositions with reduced beta-casein a1 and related methods |
US9814733B2 (en) | 2012-12-31 | 2017-11-14 | A,arin Pharmaceuticals Ireland Limited | Compositions comprising EPA and obeticholic acid and methods of use thereof |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9662307B2 (en) | 2013-02-19 | 2017-05-30 | The Regents Of The University Of Colorado | Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
US10172818B2 (en) | 2014-06-16 | 2019-01-08 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
EP3215149A4 (en) | 2014-11-06 | 2018-06-27 | Northwestern University | Inhibition of cancer cell motility |
MA41611A (fr) | 2015-02-23 | 2018-01-02 | Omthera Pharmaceuticals Inc | Préparations en milli-capsules comprenant des acides gras polyinsaturés libres |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
FR3061151B1 (fr) * | 2016-12-26 | 2019-05-24 | Belles Feuilles | Procede et systeme pour conditionner un compose lipidique en doses, capsules de compose lipidique ainsi obtenues et applications de ces capsules. |
FR3061019B1 (fr) * | 2016-12-26 | 2019-05-24 | Belles Feuilles | Procede et systeme pour conditionner des composes lipidiques pour alicaments ou medicaments. |
US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
BR112021005580A2 (pt) | 2018-09-24 | 2021-06-29 | Amarin Pharmaceuticals Ireland Limited | usos de éster etílico de ácido eicosapentaenoico (e-epa) para reduzir o risco de eventos cardiovasculares em um indivíduo |
KR200490037Y1 (ko) | 2019-04-17 | 2019-09-11 | 트랜드 주식회사 | 원터치 작동방식 욕실 청소용 물분사 헤드 |
EP3972430A1 (en) * | 2019-05-23 | 2022-03-30 | Evonik Operations GmbH | Preparation for use in enhancing formation of short-chain fatty acids (scfas) |
US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8505569D0 (sv) * | 1985-11-25 | 1985-11-25 | Aco Laekemedel Ab | Enteralt preparat |
DE3863678D1 (de) * | 1987-04-27 | 1991-08-22 | Efamol Holdings | Lithiumsalze enthaltende pharmazeutische zubereitungen. |
US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
GB2223943A (en) * | 1988-10-21 | 1990-04-25 | Tillotts Pharma Ag | Oral disage forms of omega-3 polyunsaturated acids |
WO1994012159A1 (en) * | 1992-11-30 | 1994-06-09 | Pfizer Inc. | Supported liquid membrane delivery devices |
US5411988A (en) * | 1993-10-27 | 1995-05-02 | Bockow; Barry I. | Compositions and methods for inhibiting inflammation and adhesion formation |
GB9509764D0 (en) * | 1995-05-15 | 1995-07-05 | Tillotts Pharma Ag | Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids |
-
1995
- 1995-05-15 GB GBGB9509764.8A patent/GB9509764D0/en active Pending
-
1996
- 1996-05-09 TW TW085105489A patent/TW397683B/zh not_active IP Right Cessation
- 1996-05-13 HU HU9900337A patent/HU227282B1/hu unknown
- 1996-05-13 CN CN96193911A patent/CN1104237C/zh not_active Expired - Lifetime
- 1996-05-13 JP JP8534539A patent/JPH11509523A/ja active Pending
- 1996-05-13 BR BR9608785A patent/BR9608785A/pt not_active IP Right Cessation
- 1996-05-13 PL PL96323362A patent/PL184085B1/pl unknown
- 1996-05-13 SK SK1523-97A patent/SK282062B6/sk not_active IP Right Cessation
- 1996-05-13 ES ES96916052T patent/ES2240995T3/es not_active Expired - Lifetime
- 1996-05-13 PT PT96916052T patent/PT825858E/pt unknown
- 1996-05-13 AT AT96916052T patent/ATE294575T1/de active
- 1996-05-13 KR KR1019970708110A patent/KR100427112B1/ko not_active IP Right Cessation
- 1996-05-13 CA CA002221356A patent/CA2221356C/en not_active Expired - Lifetime
- 1996-05-13 US US08/687,329 patent/US5792795A/en not_active Expired - Lifetime
- 1996-05-13 CZ CZ19973607A patent/CZ288560B6/cs not_active IP Right Cessation
- 1996-05-13 EP EP96916052A patent/EP0825858B1/en not_active Expired - Lifetime
- 1996-05-13 IL IL11824096A patent/IL118240A/xx not_active IP Right Cessation
- 1996-05-13 DK DK96916052T patent/DK0825858T3/da active
- 1996-05-13 DE DE69634693T patent/DE69634693T2/de not_active Expired - Lifetime
- 1996-05-13 AU AU58955/96A patent/AU702692B2/en not_active Expired
- 1996-05-13 WO PCT/EP1996/002038 patent/WO1996036329A1/en active IP Right Grant
- 1996-05-15 ZA ZA9603854A patent/ZA963854B/xx unknown
-
1997
- 1997-11-13 NO NO19975218A patent/NO320780B1/no not_active IP Right Cessation
-
1998
- 1998-04-30 US US09/069,751 patent/US5948818A/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW397683B (en) | Treatment of inflammatory bowel disease using oral dosage forms of <omega>-3 polyunsaturates acids | |
US4824672A (en) | Method and composition for reducing serum cholesterol | |
KR102193214B1 (ko) | 오메가-3 지방산 에스테르 조성물 | |
Seidner et al. | An oral supplement enriched with fish oil, soluble fiber, and antioxidants for corticosteroid sparing in ulcerative colitis: a randomized, controlled trial | |
US4883788A (en) | Method and composition for reducing serum cholesterol | |
EP3062785B1 (en) | Enteric soft capsules comprising polyunsaturated fatty acids | |
US10188623B2 (en) | Enhanced bioavailability of polyunsaturated fatty acids | |
CN102526733A (zh) | 用于预防心血管事件发病的组合物 | |
KR20110058881A (ko) | 지방산 오일-함유 에멀션을 포함한 폴리사카라이드 캡슐 | |
EA011637B1 (ru) | Лечение с использованием омега-3 жирных кислот и агониста и/или антагониста ppar и их комбинированный продукт | |
CN107233337A (zh) | 含有epa和心血管剂的药物组合物以及使用其的方法 | |
WO2011048493A1 (en) | Coated capsules and tablets of a fatty acid oil mixture | |
TW568783B (en) | A pharmaceutical composition for the treatment of inflammatory conditions in mammals | |
Westberg et al. | Effect of MaxEPA in patients with SLE: A double-blind, crossover study | |
GB2300807A (en) | Oral dosage forms of omega-3 polyunsaturated acids for the treatment of inflammatory bowel disease | |
Chawla et al. | Effect of N-3 polyunsaturated fatty acid supplemented diet on neutrophil-mediated ileal permeability and neutrophil function in the rat. | |
CA2950444C (en) | Enhanced bioavailability of polyunsaturated fatty acids | |
CN108904807A (zh) | 二甲双胍复配组合物及其应用 | |
AU2018440781A1 (en) | Capsule, tablet or pill | |
JPH07233062A (ja) | 人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物 | |
Christensen | Use of a Mixed-Oil Lipid Emulsion in Infants with Intestinal Failure Associated Liver Disease who were Receiving a Soybean Oil Emulsion | |
MXPA97008758A (en) | Treatment of inflammatory bowel disease using formats of oral dose of acids 3-omega-poliinsatura | |
CA1309352C (en) | Method and composition for reducing serum cholesterol | |
JP2005247871A (ja) | 人工透析患者の副甲状腺機能亢進症治療組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |